GlassScriptPhysician profile
John S Hayes
NPI 1154520476
$7,033.70
in general payments reported to CMS, 2019-2025
28 companies · $881 in 2025
The $881 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $481 · 2021: $800 · 2022: $1,922 · 2023: $1,594 · 2024: $847 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,231 · Education: $91.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,231.03 |
| Education | $91.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $1,831.79 | 2021-2025 | Nxstage System One, Pureflow Sl, Liberty Select Cycler |
| Horizon Therapeutics Plc | $1,089.40 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $684.62 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $564.98 | 2019-2025 | Krystexxa, Tavneos, Uplizna |
| Vifor Pharma, INC. | $350.41 | 2020-2023 | Veltassa |
| Aurinia Pharma U.S., INC. | $330.35 | 2021-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $278.14 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $261.23 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $230.64 | 2022-2025 | Acthar |
| Tosoh Bioscience, INC. | $169.00 | 2019 | |
| Fresenius USA Marketing, INC. | $166.77 | 2020-2024 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $160.77 | 2019-2024 | Jynarque |
| Stryker Corporation | $142.48 | 2020 | |
| Avinger INC. | $120.23 | 2019 | |
| Ani Pharmaceuticals, INC. | $113.67 | 2024-2025 | Purified Cortrophin Gel |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.79 | 2023-2025 | Jardiance |
| W. L. Gore & Associates, INC. | $83.53 | 2019 | |
| Lilly USA, LLC | $76.78 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $69.32 | 2023-2024 | |
| Akebia Therapeutics INC | $47.97 | 2020-2024 | Vafseo, Auryxia |
| Cormedix INC. | $44.80 | 2024-2025 | Defencath, Defencath |
| Renalytix Ai, INC. | $35.84 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Glaxosmithkline, LLC. | $23.37 | 2022 | |
| Ardelyx, INC. | $18.99 | 2024 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $16.61 | 2024 | Ultomiris |
| Pacira Pharmaceuticals Incorporated | $16.03 | 2020 | |
| Opko Pharmaceuticals, LLC | $15.80 | 2022 | |
| Travere Therapeutics, INC. | $0.39 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.